HIF-1α inhibition has also been shown to abrogate PD-L1 mediated immune evasion by suppressing PD-L1 expression on tumor cells and tumor-associated macrophages, thereby fostering the implementation of combination therapies based on HIF inhibitors and anti-PD-L1 monoclonal antibodies [41]. Here, HIF1A is linked to neoplasm.